Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Aureus Pharma participates in biointelligence R&D programme

Share this on social media:

Aureus Pharma is participating in the EUR 118.2m Biointelligence R&D programme, designed to promote the use of systemic modelling and simulation tools to exploit biomedical databases to improve research efficiency.

The BioIntelligence R&D programme will be coordinated by Dassault Systèmes, and involve leading life science industry players such as sanofi-aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, as well as public research institutes like Inserm, Inria and Genopole, and SMEs specialised in bioinformatics such as Aureus and Sobios. This programme will account for a total of EUR 118.2 million of eligible expenditure from which EUR 46.3 million will be from OSEO, a public company supporting innovation and growth of SMEs.

BioIntelligence will promote the use of systemic modelling and simulation tools to exploit biomedical databases. This approach, based on the Product Lifecycle Management (PLM) method used by manufacturing industries, will enable life science industries to optimise the research phases of drug development.

Aureus will participate in the development of the Knowledge Management layer of the planned system and build new innovative content in therapeutic areas like oncology, as well as in the area of nuclear receptors, proteases inhibitors and life science semantics. In addition to providing significant funding, this programme will also enable Aureus to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols or regulation of physiological responses. Aureus Pharma expects to receive aids for a total of EUR 3.5 million but further details are not being made public.